Biodistribution studies of boronophenylalanine-fructose in melanoma and brain tumor patients in Argentina

Appl Radiat Isot. 2004 Nov;61(5):1095-100. doi: 10.1016/j.apradiso.2004.05.013.

Abstract

A study of the (10)B-enriched p-boronophenylalanine-fructose complex ((10)BPA-F) infusion procedure in potential BNCT patients, including four melanoma of extremities and two high-grade gliomas (glioblastoma and ganglioglioma) was performed. T/B and S/B ratios for (10)B concentrations in tumor (T), blood (B) and skin (S) were determined. The T/B ratio for the glioblastoma was in the 1.8-3.4 range. The ganglioglioma did not show any significant boron uptake. For the nodular metastasic melanoma T/B values were between 1.5 and 2.6 (average 2.1+/-0.4), corresponding to the lower limit of the mean values reported for different melanoma categories. This result might suggest a lower boron uptake for nodular metastasic melanomas. S/B was 1.5+/-0.4. An open two-compartment pharmacokinetic model was applied to predict the boron concentration during the course and at the end of a BNCT irradiation.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Argentina
  • Boron / blood
  • Boron / pharmacokinetics
  • Boron Compounds / pharmacokinetics*
  • Boron Compounds / therapeutic use*
  • Boron Neutron Capture Therapy*
  • Brain Neoplasms / metabolism*
  • Brain Neoplasms / radiotherapy*
  • Female
  • Fructose / analogs & derivatives*
  • Fructose / pharmacokinetics*
  • Fructose / therapeutic use*
  • Ganglioglioma / metabolism
  • Ganglioglioma / radiotherapy
  • Glioblastoma / metabolism
  • Glioblastoma / radiotherapy
  • Humans
  • Male
  • Melanoma / metabolism*
  • Melanoma / radiotherapy*
  • Melanoma / secondary
  • Middle Aged

Substances

  • 4-boronophenylalanine-fructose
  • Boron Compounds
  • Fructose
  • Boron